drugset / Trial / NCT06121180
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Phase 2
Recruiting
32 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Genzyme, a Sanofi Company · collabRegeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Timeline
- Start
- 2024-11-04
- Primary completion
- 2030-10-31
- Completion
- 2030-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 4 mg/kg | Intravenous |
| Subject | Cemiplimab | Monoclonal antibody | 350 mg | Intravenous |